News
The Clinical Research and Clinical Trials Unit obtains the ISO 9001:2015 recertification
The IDIBELL Clinical Research and Clinical Trials Unit (UICEC), managed by the HUB’s Clinical Pharmacology service and led by the head of this service, Dr. Pilar Hereu, achieved recertification of the quality management system.
The association for epilepsy “If I can, you too #epilep” donates 10,000 euros to research
The funds will be directed to the IDIBELL and Bellvitge Hospital research group in Neurological Diseases and Neurogenetics.
Researchers describe genetic variants that increase vulnerability to gambling addiction
This IDIBELL and Bellvitge Hospital study shows that six variants of the gene family that codes for these factors are closely associated with more vulnerability to gambling addiction.
The educational tandem of IDIBELL and the Institut Bellvitge closes the academic year having increased the number of activities and students involved
The educational tandem formed by the Institut Bellvitge and IDIBELL has closed the 2021-2022 academic year with the publication of the fifth issue of Life & Science magazine, the project carried out by 3rd year ESO students and which includes all the activities that the educational center carries out with researchers and professionals from IDIBELL.
An MRI could predict patients with epilepsy who would not suffer cognitive impairment with surgery
A study by IDIBELL, Bellvitge Hospital, and the University of Barcelona identifies, through magnetic resonance imaging, significant differences in the connectivity of several subregions of the hippocampus between patients with epilepsy who, after surgery, suffer impairments in verbal learning and those who do not.
Rosa Benet is the new IDIBELL’s managing director
The IDIBELL Board of Trustees approved the appointment of Rosa Benet as the Center’s new Director of Management. Benet is a specialist in financial control with proven experience and responsibilities in multinational environments.
A clinical trial shows positive results for the most common cutaneous lymphoma treatment with an immunosuppressive drug
Dr. Cristina Muniesa and Dr. Octavi Servitje, from the Dermatology Service of the Bellvitge University Hospital (HUB) and IDIBELL researchers, participated in this study that evaluates the use of topical pimecrolimus in mycosis fungoides and was published in the prestigious journal The Lancet Haematology.
The HUB-ICO-IDIBELL biobank renews the ISO 9001:2015 certification
The HUB-ICO-IDIBELL Biobank has renewed the certification for the ISO 9001 standard, a quality standard recognized nationally and internationally based on continuous process improvement, and that demonstrates the organization’s commitment to quality service and customer satisfaction.
Discovered epigenetic alterations associated with the COVID-19 related severe inflammatory syndrome in childhood
Dr. Aurora Pujol from IDIBELL and Dr. Manel Estaller from the Josep Carreras Leukaemia Research Institute identified an epigenetic signature associated to the development of the Multisystem Inflammatory Syndrome in Children (MIS-C) after a SARS-CoV-2 virus infection.